Almotriptan EP Impurity D (Fumarate Salt)
✓
100% accuracy
of data
24/7 scientific
support
⬡
0% tolerance in
quality of product

Stock Locations

  • New Jersey, USA
  • Czech Republic, EU
  • Mumbai, India

* Stock subject to availability.

Documentation

Download MSDS

Download Sample COA

Includes: HPLC, MASS/LC-MS, 1H NMR, FT-IR, Potency, Structure Elucidation Report (SER), and additional analytical data depending on the product.

1246860-65-0Almotriptan EP Impurity D (Fumarate Salt)

● In Stock

Catalogue No.:VE0025037
CAS No.:1246860-65-0
Mol. Formula:C17H23N3O4S
Mol. Weight:365.46 g/mol

Additional information on CAS 1246860-65-0

Parent drug

Almotriptan

IUPAC Name

2-(5-[(Pyrrolidin-1-yl-sulfonyl)methyl]-1H-indol-3-yl)ethan-1-amine hemifumarate

Pharmacopoeial Synonyms

Almotriptan Related Compound B

Other Synonyms

Didesmethyl almotriptan hemifumarate

Smiles

NCCC1=CNC2=CC=C(CS(N3CCCC3)(=O)=O)C=C21.O=C(O)/C=C/C(O)=O

InChI

InChI=1S/C15H21N3O2S.C4H4O4/c16-6-5-13-10-17-15-4-3-12(9-14(13)15)11-21(19, 20)18-7-1-2-8-18;5-3(6)1-2-4(7)8/h3-4, 9-10, 17H, 1-2, 5-8, 11, 16H2;1-2H, (H, 5, 6)(H, 7, 8)/b;2-1+

Description

Almotriptan EP Impurity D (Fumarate Salt) | CAS 1246860-65-0 | also known as Almotriptan Related Compound B or Didesmethyl almotriptan hemifumarate | is a synthesis and degradation impurity arising from demethylation of the parent molecule during manufacturing or storage. The hemifumarate form influences solubility and crystal morphology | necessitating tailored control strategies. Analytical identification and quantification are routinely performed by validated HPLC with UV detection | LC-MS for mass confirmation and 1H NMR for structural verification. Establishing robust specification limits and stability-indicating methods for this impurity is critical to meet pharmacopoeial requirements and ensure consistent drug substance quality.

Request a Quote

"*" indicates required fields

This field is for validation purposes and should be left unchanged.
Products quotation
Name
Url